Sai Life Science Share Price

Pharmaceuticals company Sai Life Science announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations for Q4FY26 stood at Rs 6,021.39 million, representing a growth of 3.91% YoY compared to Rs 5,795.07 million in Q4FY25, and an increase of 8.21% QoQ from Rs 5,564.64 million in Q3FY26. Total Income for Q4FY26 was Rs 6,176.58 million, an increase of 4.85% YoY against Rs 5,891.06 million in Q4FY25, and a growth of 9.35% QoQ compared to Rs 5,648.44 million in Q3FY26. Profit after tax (PAT) for Q4FY26 reached Rs 1,042.36 million, registering a growth of 18.09% YoY from Rs 882.69 million in Q4FY25, and a 3.85% QoQ increase from Rs 1,003.75 million in Q3FY26. For the full year FY26, Revenue from operations was Rs 21,924.92 million, showcasing a strong growth of 29.38% YoY compared to Rs 16,945.70 million in FY25. Total Income for FY26 stood at Rs 22,416.20 million, up 29.47% YoY from Rs 17,313.49 million in FY25. Profit after tax (PAT) for FY26 more than doubled, surging by 105.08% YoY to Rs 3,489.10 million from Rs 1,701.32 million in FY25. Standalone Financial Highlights: Revenue from operations for Q4FY26 was Rs 5,943.40 million, up 4.82% YoY from Rs 5,670.06 million in Q4FY25, and an increase of 8.22% QoQ from Rs 5,491.79 million in Q3FY26. Total Income for Q4FY26 reached Rs 6,100.85 million, growing 5.77% YoY against Rs 5,768.25 million in Q4FY25, and 9.41% QoQ from Rs 5,576.26 million in Q3FY26. Profit after tax (PAT) for Q4FY26 stood at Rs 1,025.32 million, a 14.01% YoY increase from Rs 899.35 million in Q4FY25, and a 5.02% QoQ growth from Rs 976.30 million in Q3FY26. For the full year FY26, Revenue from operations stood at Rs 21,532.26 million, up 31.13% YoY compared to Rs 16,420.48 million in FY25. Total Income for FY26 was Rs 22,023.57 million, an increase of 31.14% YoY from Rs 16,793.83 million in FY25. Profit after tax (PAT) for FY26 experienced substantial growth of 96.86% YoY, reaching Rs 3,414.81 million compared to Rs 1,734.62 million in FY25. Business & Segment Highlights: Segment Performance: The Group operates in a single business segment, which is providing "Contract Research, Development and Manufacturing Services (CRDMO)". IPO Fund Utilization: The company successfully utilized 100% of its net IPO proceeds, which amounted to Rs 9,098.84 million. Of this, Rs 7,200.00 million was utilized for the repayment/prepayment of outstanding borrowings, and Rs 1,898.84 million was used for general corporate purposes. Exceptional Items (Labour Codes Impact): Following the Government of India's notification of new Labour Codes, the company reassessed its employee benefits liability. While Q3FY26 saw a charge of Rs 82.93 million, a reassessment based on revised remuneration structures yielded a credit of Rs 2.92 million in Q4FY26. The net exceptional expense for FY26 stood at Rs 80.01 million. ESOP Grant: During FY26, the Nomination and Remuneration Committee approved the grant of 205,000 employee stock options under the Sai Life Sciences Limited Management ESOP Scheme – 2018, effective 13 November 2025. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth. While the operating environment remains dynamic, we believe the long-term fundamentals of innovation-led outsourcing and supply chain diversification continue to remain strong, and we are well positioned to participate meaningfully in this opportunity." Siva Chittor, Chief Financial Officer, Sai Life Sciences, added, “FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities. Result PDF

• Trendlyne
• 1 week 4 days ago

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

• Business Standard
• 2 weeks 4 days ago

The brokerage noted that Sai Life remains relatively small compared with its addressable market, with FY25 sales of about $200 million, providing significant room for expansion

• Business Standard
• 2 months 2 weeks ago